Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trialThomas Engstrøm, Lars Køber, Henning Kelbæk et al.|The Lancet|2015Cited by 966
Severe mental illness: cardiovascular risk assessment and managementChristoffer Polcwiartek, René Ernst Nielsen, Daniel J. Friedman et al.|European Heart Journal|2024Cited by 76
Beta-Blockers after Myocardial Infarction in Patients without Heart FailureJohn Munkhaugen, Gro Egholm, Svend Eggert Jensen et al.|New England Journal of Medicine|2025Cited by 73
β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trialsXavier Rosselló, John Munkhaugen, Eva Prescott et al.|The Lancet|2025Cited by 63
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point studyJohn Munkhaugen, Dan Atar, Vidar Ruddox et al.|American Heart Journal|2018Cited by 50